People · Operator
Named in public records as an officer, director or promoter · active 2011–2016 · Manufacturing, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| FRX Polymers, Inc. | — | Manufacturing | Series B | $55.2M | $248.3M | 2013 |
| Acasti Pharma Inc. | — | Biotechnology | Series A | $23.0M | $58.5M | 2011 |
Marc Lebel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marc Lebel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Derby | 1 | 5 |
| Donald Olds | 1 | 4 |
| Ross Haghighat | 1 | 4 |
| A. Brian Davis | 1 | 3 |
| Bernhard Mohr | 1 | 3 |
| MARTIN GODBOUT | 1 | 3 |
| Ronald Denis | 1 | 2 |
| JACK LEVY | 1 | 2 |
| Henri Harland | 1 | 2 |
| Edward Neugeboren | 1 | 2 |
| Tina Sampalis | 1 | 2 |
| Pierre Lebel | 1 | 2 |
| Robert J. DelAversano | 1 | 2 |
| Linda P. O'Keefe | 1 | 2 |
| Michel Chartrand | 1 | 2 |
| Chris Joyce | 1 | 2 |
| Dieter Freitag | 1 | 1 |
| Jan Pleun Lens | 1 | 1 |
| Amir Ohad | 1 | 1 |
| Ross A. Haghighat | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.